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ABSTRACT 
 
Cluster Headache (CH) is an uncommon headache disorder, with severe implications for the 
individual patient. The headache is excruciating, unilateral and appearing in attacks. It is common 
that CH patients show ipsilateral associated symptoms, like for example conjunctival injection, 
lacrimation and nasal congestion. The pathophysiology of CH is still not completely understood. 
The overall objective of this thesis was to explore if inflammation and nitric oxide participate in the 
pathophysiology of CH. 
 
Study I 
The aim of study I was to identify differentially expressed genes during clinical phases of CH, 
assuming that changes of pathophysiological importance would also be observed in peripheral 
venous blood. Blood samples were drawn at 3 consecutive occasions from 3 episodic CH 
patients: during attacks, between attacks and in remission, and at 1 occasion from 3 matched 
controls. Global gene expression was analyzed with microarray tehnology using the Affymetrix 
Human Genome U133 2.0 Plus GeneChip® Set. In addition, quantitative RT-PCR on S100P 
gene expression was analyzed in 6 patients and 14 controls. Small differences were seen 
intraindividually and large differences interindividually. Intraindividual comparisons showed 
upregulation of several S100 calcium binding proteins; S100A8 (calgranulin A), S100A12 
(calgranulin C), and S100P during active phase of the disease compared to remission. The 
S100A8 and S100A12 proteins are considered markers of non-infectious inflammatory disease, 
while increased levels of S100P have been associated to different forms of cancer. RT-PCR 
analysis of S100P confirmed the Affymetrix´ results. 
 
Study II 
We investigated the cytokine interleukin-2 (IL-2) as a possible marker of immune system 
involvement in the pathophysiology of CH. Eight episodic CH patients and 16 healthy headache-
free control subjects matched for age and gender were studied. Venous blood samples were 
drawn from the CH patients at three occasions; during active period between headache attacks, 
during attack and in remission. Venous blood samples were drawn once from each control 
subject. We analyzed IL-2 gene expression, using quantitative real-time polymerase chain 
reaction (RT-PCR). Patients with CH had significantly increased relative IL-2 gene expression 
levels during active period between headache attacks compared to during attacks, remission and 
controls. 
  
Study III 
In this study we have investigated white blood cell accumulation into potential inflammatory areas 
intracranially in 14 CH patients, both in active period and in remission, and 5 control subjects, 
with single photon emission computer tomography (WBC-SPECT). To enable precise definition of 
regions of interest (ROI:s) in the brain, all CH patients and control subjects also underwent 
magnetic resonance imaging (MRI) of the brain. We found no statistically significant difference in 
99mTc-labeled WBC uptake between CH patients in active period and controls. Furthermore CH 
patients in active period were not significantly different in uptake compared to CH patients in 
remission. 
 
Study IV 
We investigated the role of nitric oxide (NO) in CH, by measuring its oxidation products, nitrite 
and nitrate, in the cerebrospinal fluid (CSF). We collected CSF from 14 episodic CH patients. 
Lumbar puncture was performed at two occasions: in active period between headache attacks, 
and in remission, not earlier than three weeks after their last headache attack. Eleven healthy 
volunteers served as controls. To estimate NO production, we determined the levels of NO-
oxidation end products (NOx), that is, the sum of nitrite and nitrate, by using capillary 
electrophoresis (CE). CH patients in active period had significantly increased NOx levels 
compared with those in remission and control subjects. CH patients had also significantly 
enhanced NOx levels in remission compared to control subjects. 
 
Keywords: Cluster Headache, gene expression, inflammation, WBC-SPECT, nitric oxide. 
 
 
2
 
LIST OF PUBLICATIONS 
 
 
I. Christina Sjöstrand, Kristina Duvefelt, Anna Steinberg, Ingela Nilsson 
Remahl, Elisabet Waldenlind, Jan Hillert. 
Gene Expression Profiling in Cluster Headache: A Pilot Microarray 
Study. 
                  Headache 2006 Nov-Dec; 46(10):1518-34  
 
 
 
 
II. Anna Steinberg, Christina Sjöstrand, Ajith Sominanda, 
           Anna Fogdell-Hahn, Ingela Nilsson Remahl.   
Interleukin-2 gene expression in different phases of episodic 
cluster headache – a pilot study. 
Acta Neurol Scand. 2010 Sep 29. doi: 10.1111/j.1600-
0404.2010.01434.x. [Epub ahead of print] 
                
 
 
 
III. Anna Steinberg, Rimma Axelsson, Lars Ideström, Susanne Müller, 
Ingela Nilsson Remahl. 
White blood cell SPECT during active period of Cluster Headache 
and in remission. 
Accepted for publication in European Journal of Neurology 
 
 
 
IV. Anna Steinberg, N Peter Wiklund, Lou Brundin, Ingela Nilsson Remahl. 
Levels of nitric oxide metabolites in cerebrospinal fluid in cluster 
headache. 
Cephalalgia 2010 Jun; 30(6):696-702 
 
 
 
 
 
 
 
 
 
 
 
 
 
3
ABBREVIATIONS 
 
 
BBB  Blood brain barrier 
CE Capillary electrophoresis 
CGRP Calcitonin gene related peptide 
CH                 Cluster Headache 
CSF Cerebrospinal fluid 
DBS Deep brain stimulation 
GCA Giant cell arthritis 
GCOS Gene Chip® Operating Software (Affymetrix) 
IL-2 Interleukin-2 
IQR Interquartile range 
LP Lumbar puncture 
MM Mismatch 
MRI Magnetic resonance imaging 
MP-RAGE Magnetization-prepared rapid gradient echo 
NO Nitric oxide 
NOS Nitric oxide synthases 
eNOS Endothelial NOS 
iNOS Inducible NOS 
nNOS Neuronal NOS 
NOx NO-oxidation end products; nitrite and nitrate 
ONS Occipital nerve stimulation 
PET Positron emission tomography 
PM Perfect Match 
ROI Region of interest 
Q-RT-PCR Quantitative Real-time polymerase chain reaction 
99mTC-LABELED WBC  99mTecnetium-labeled white blood cells 
TNC Trigeminal nucleus caudalis 
TVS Trigeminovascular system 
WBC-SPECT      White blood cell single photon emission computer tomography 
VIP Vasoactive intestinal polypeptide 
 
                             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4
INTRODUCTION 
 
 
Clinical description of cluster headache (CH) 
 
Cluster Headache is an extremely painful headache disorder characterized 
by periods (clusters) of recurrent, unilateral attacks of excruciating pain with a 
retro-orbital maximum. The attack duration varies from 15 - 180 minutes1. CH 
usually appears between 20 and 65 years of age2 and during active phase the 
attacks occur from once every second day to 8 times a day. Most patients show 
ipsilateral symptoms; conjunctival injection, lacrimation, nasal congestion, 
rhinorrhoea, eyelid oedema, forehead/facial sweating, miosis and/or ptosis, 
indicating ipsilateral autonomic dysfunction. Episodic CH occurs in periods lasting 
between 7 days to 1 year, separated by pain-free periods, lasting 1 month or 
longer. About 10 % of the patients develop chronic CH without remission periods1. 
 
 
 
 
 
Epidemiology 
 
An established estimation of the prevalence of CH, i.e. the proportion of the 
population with current CH, is almost 0.1%, (70-90/100.000)2. A similar 
prevalence was reported in a survey of 18-year old Swedish men, 0.09%3 and in 
an Italian study,  around 0.07% (56-69 per 100.000)4 . 
 
A lifetime prevalence, i.e. the proportion of the population with previous or 
current CH, of 0.38%, was found in a study from Vågå, Norway, in which the 
diagnosis was made by face-to-face interviews5. These higher prevalence data 
are supported by the result from the Swedish twin registry, showing a lifetime 
prevalence of 0.2%6. CH is rare in children2.  
 
 
 
5
CH is more common in men. Earlier studies have shown a male: female 
ratio 5-6:15, 7, but over the last years this dominance has been reported to be less 
prominent, 2.5-3.5:18. This change may be caused by a higher observance for 
the disorder in women, life style changes, or unknown factors. 
 
Genetic aspects 
 
Until recently CH was regarded as a sporadic rather than an inherited 
disorder. Data from family and twin studies have suggested a heritable 
component, and it has been estimated that first-degree relatives of CH patients 
have a 5-18 times and second-degree relatives 1-3 times higher risk to develop 
CH than the general population8-10. The variation of the reported risk can partly 
be explained by methodological differences. Studies from segregation analysis 
have suggested than an autosomal dominant gene with incomplete penetrance 
occur in some families and an autosomal recessive inheritance in others11.  
 
The calcium channel gene (CACNA1A) was in focus for genetic research in 
neurological diseases around ten years ago, because of mutations in the gene 
found to be responsible for several episodic neurologic disorders, e.g. familial 
hemiplegic migraine. The CACNA1A gene has also been studied in CH, but has 
been judged to be of minor importance12, 13.   
 
The role of NO in CH pathophysiology has been extensively discussed. In 
an association study of 91 CH patients and 111 matched controls, polymorphism 
of three NOS genes (nNOS, iNOS, and eNOS) were studied. No significant 
genetic differences between patients and controls regarding NOS were found14.  
 
PET studies have established that hypothalamus has a pivotal role in CH15. 
As a consequence, genes involved in regulation of the circadian rhythm have 
been of interest. The hypocretin neuropeptides, hypocretin-1(orexin-A) and 
hypocretin-2 (orexin-B), are expressed in a small population of neurons in the 
lateral hypothalamus and project into all brain regions. They interact with two 
receptors; HCRTR1 and HCRTR28, 9. A positive association study was published 
in 2004, when a highly significant association between the 1246G>A 
polymorphism of the HCRTR2 gene and CH was found8, 9. Thereafter several 
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genetic studies have been performed regarding the HCRTR2 gene, with 
divergent results. Two of these studies indicate an association between the 
HCRTR2 gene and CH16, 17, while one did not18. 
 
 
 
         Pathophysiology  
 
The pathophysiology of CH is largely unknown, but the discussion has 
mainly been focused around six mechanisms;  vasodilation19, 20,  
inflammation 21, 22,  hypothalamic dysfunction15, 23, trigeminovascular system 
activation24, autonomic system imbalance24, 25 and increase of nitric oxide 
levels 6, 27.  
n of cranial 
vesse
avasation, neurogenic inflammation 
and sensitizing of meningeal receptors24, 34.  
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Vasodilation 
 The ipsilateral ophthalmic artery is shown to be markedly dilated during CH 
attacks20, although dilation of cranial vessels is regarded to be unspecific and 
observed in many different headache syndromes19. Pain inducing capsaicin 
injection into the forehead, in headache-free volunteers, caused dilatio
ls, probably mediated by the trigeminoparasympathetic reflex19. 
Early observations of precipitation of CH by vasodilators such as alcohol, 
histamine28-30 and nitroglycerine31 suggested that vasodilation may be essential 
for the generation of the pain during attacks. Subsequently, cerebral blood flow 
studies32, 33 were unable to support a primary role of vasodilation in CH19, 
although vasodilation may be involved as a pathophysiological step towards 
generation of pain. Critical steps may be activation of the trigeminal vascular 
system leading to vasodilation, protein extr
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Inflammation 
 
Inflammation is characterized by five cardinal signs; redness, heat, swelling, 
pain and loss of function. Marked vascular changes, including vasodilation and 
increased permeability, which are induced by the actions of various inflammatory 
mediators, make it possible for WBC to migrate out into the tissue35. 
 
In the clinical routine care corticosteroids usually have a positive effect 
when CH patients suffer from frequent CH attacks, suggesting a role for 
immunological mechanisms in the disease. Earlier studies on inflammatory 
mechanisms have shown partially conflicting results. Transient recurrent venous 
vasculitis in the cavernous sinus has been suggested by some authors 22,36. One 
study of episodic CH patients showed neither clinical symptoms nor changes in 
routine laboratory tests in support of a systematic inflammatory disorder37. 
Another study showed a trend of an immune response that reacted differently 
than healthy volunteers and patients with active biopsy-verified giant cell arthritis 
(GCA). Pro-inflammatory adhesion molecules appeared down-regulated during 
active CH period and up-regulated during remission, while a reverse pattern was 
observed among patients with GCA38. Several other studies have also shown 
changes in immune competent factors21, 39, 40.  
 
Potential inflammatory involvement in CH has been further supported by 
imaging studies. Gallium-67 citrate is picked up in areas of inflammation, and 
Gallium SPECT has shown a lesion in the region of the cavernous sinus, which 
fades as the patient moves out of cluster41. Another Gallium SPECT study, 
however, has shown that increased parasellar activity on Gallium SPECT was 
neither specific for CH, nor for the active period of episodic CH42.  
 
Inflammation is normally accompanied by the extravasation of plasma 
proteins into the surrounding tissue. The hypothesis of a sterile inflammation in 
the cavernous sinus of CH patients was first tested in year 2000 with 
radiolabelled human serum albumin ( 99mTc-HSA) uptake and SPECT/MRI by 
Goebel et al 43 who reported albumin leakage into the cavernous sinus 
ipsilaterally to the pain in CH patients during active CH period. A subsequent 
study by Schuh-Hofer et al in 2006, however, using the same technique, were 
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unable to confirm these findings, since no statistically significant difference was 
seen between the 99mTc-HSA uptake in the ipsilateral cavernous sinus before 
and after induction of a CH attack and there was no evidence of 99mTc-HSA 
extravasation in the cavernous sinus in active period compared with remission 
phase 44.  
  
The role of neurogenic inflammation by release of vasoactive peptides, 
such as calcitonin gene related peptide (CGRP) and substance P, from trigeminal 
fibers has received increased attention over the years24, 25, 45.  
 
 
 
 
Hypothalamic activation  
CH attacks tend to occur with circadian rhythmicity; consequently 
hypothalamus is thought to be involved in CH pathophysiology, being regarded 
as the place of the “biological clock”. Hormonal studies have shown alterations in 
plasma levels of melatonin, cortisol, testosterone, prolactine, growth hormone, 
gonadotrophins and thyrotropins in CH patients compared with controls, 
indicating that hypothalamus is involved in CH23, 46-48. PET-studies have shown 
activation of hypothalamic ipsilateral grey matter in patients who had acute 
attacks, which has been interpreted as a dysfunction in hypothalamus in CH 
patients 15. Morphometric studies using functional MRI have also observed an 
increased volume of the grey matter of the corresponding area in hypothalamus49. 
 
 
 
Trigeminovascular system activation   
The trigeminovascular system (TVS) includes neurons located within the 
trigeminal ganglion that projects both peripherally and centrally. At the peripheral 
level, the trigeminal nerve innervates pain-sensitive supratentorial structures 
such as main arteries and dura mater. Centrally projecting fibers synapse in the 
brain stem, principally in the trigeminal nucleus caudalis (TNC). In migraine it is 
hypothesized that dysfunction in the brainstem may cause dilation of arteries 
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innervated by the trigeminal nerve. This might lead to plasma protein 
extravasation, neurogenic inflammation and sensitizing of meningeal receptors. 
Subsequently, a trigeminal sensory pain response will be activated, in which 
signals are transferred to the brainstem, and further on to thalamus and the 
cortical areas, resulting in the experience of pain. A release of vasoactive 
peptides, such as calcitonin gene related peptide (CGRP) and substance P, from 
trigeminal fibers accelerates the neurogenic inflammation and vasodilation 50, 51. 
For CH the principal TVS mechanism might be similar to that in migraine, with the 
exception that the “start focus” probably is situated in the hypothalamus. CGRP is 
a marker of the TVS and increased levels have been found in blood from the 
external jugular vein during CH attacks, which the authors conclude as an 
evidence for activation of the TVS 24. 
 
 
Autonomic nervous system imbalance  
During CH attacks most patients suffer from autonomic symptoms such as 
ipsilateral lacrimation, conjunctival injection, nasal congestion, rhinorrhoea, 
miosis and ptosis.  
 
Ipsilateral lacrimation, conjunctival injection, nasal congestion and 
rhinorrhoea are caused by activation of the cranial parasympathetic outflow from 
the seventh cranial nerve25. There is also evidence that the severity of pain is 
correlated with the autonomic symptoms and the pain itself may trigger these 
symptoms52. Markedly raised levels of vasoactive intestinal polypeptide (VIP) 
have been measured during spontaneous CH attacks24. These findings were 
considered as evidence of involvement of the cranial parasympathetic nervous 
system. Sympathetic impairment with ipsilateral miosis and ptosis are also 
common, and  believed to be due to transient injury of the postganglionic fibres25. 
Some authors have suggested that the sympathetic symptoms may be caused by 
periorbital venous vasculitis, compromising the carotid canal and consequently 
the transversing sympathetic fibers22, 36. The autonomic dysregulation in CH 
might also originate centrally in association with a hypothalamic disturbance53, 54. 
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Increase of Nitric oxide levels 
 
The role of nitric oxide (NO) in CH has been discussed over the latest years. 
NO is synthesized from L-arginine by a family of enzymes, the nitric oxide 
synthases (NOS). NO diffuses freely across membranes26 and has multiple 
functions in the body. For example NO prevent platelet activation, inhibit 
monocyte adhesion and leucocyte function. Further on it is an important 
neurotransmitter and the L-arginine NO-pathway regulates the vascular tone 
acting as a potent vasodilator55. NO diffuses into vascular smooth muscle cells 
and causes vasodilation56. Apart from regulating blood flow, NO is thought to play 
a role in processing sensory information57, 58 and pain sensitisation59. In the 
trigeminal ganglion, CGRP and nitric oxide synthases (NOS) co-localize in many 
neurons60. It has been suggested that NO causes release of CGRP61, but other 
studies have not confirmed this result62, 63. It is also possible that CGRP is 
causing release of NO. In the human forearm, CGRP-induced dilation was partly 
inhibited by a NOS inhibitor64. Increased NO levels may also be an expression of 
enhanced inflammatory activity65-67. 
 
 D’Amico et al. demonstrated enhanced nitrite-levels in plasma among CH 
patients, both in active period and in remission26. The authors suggested that a 
basal hyperfunction of the L-arginine-NO pathway may occur in both phases of 
CH, while a later study was unable to confirm those results56.  
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TREATMENT 
 
 
Since the CH attacks are extremely painful there is usually a need for both 
acute and prophylactic medication. The utmost aim is to get the patient attack-
free during a bout of cluster attacks by prophylactic medication. This is difficult, 
since there is no one solution that fits all. Some patients even choose to be 
without prophylactic medication, if the CH attacks are sparse, or because of side 
effects.  
 
Acute treatment 
 
Because of the rapid onset, the severe intensity of the CH attacks and often 
short attack duration, fast acting acute therapy is needed. The acute treatment 
includes primarily sumatriptan injection, triptan nasal sprays or 100 % oxygen 
inhalation. The most effective acute treatments are sumatriptan injection 68. In a 
double-blind, placebo-controlled trial, the 5-HT1B/1D receptor agonist sumatriptan 
injected subcutaneously was effective in about 75 % of all CH patients, i.e. 
patients were pain-free within 20 minutes69, 70.  
 
Triptan nasal sprays have a slower time of onset, than sumatriptan injection. 
Nevertheless many CH patients use triptan nasal sprays since they wish to avoid 
injections. Orally administered acute medications tend in most cases to be 
ineffective, since they do not give effect fast enough. The mechanism of action 
for triptans has been related to inhibition of CGRP release from trigeminal 
neurons in vitro62, 71 and inhibition of CGRP induced vasodilation in vivo74. 
Contraindications to sumatriptan and other triptans are cardio- and 
cerebrovascular disorders and untreated arterial hypertension.  
 
In CH, oxygen treatment has an obvious role, since it can safely be used in 
patients with cardio- and cerebrovascular disorders. Oxygen inhalation has no 
known side-effects. Disadvantage of oxygen treatment, however, are that the 
effect is moderate particularly for severe attacks and patients must have access 
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to the oxygen cylinder and regulator, which is often impractical. In a smaller study, 
CH patients were treated with 100% oxygen and were released from cluster pain 
in 75% within 15 minutes72. The results were later confirmed in a double-blind, 
randomized, placebo-controlled crossover trial73. The mechanism of oxygen 
treatment is regarded as a vasoconstrictor effect74, 75.  
 
Prophylactic treatment 
 
Among several options for prophylactic treatment verapamil is generally 
accepted as the first choice76. Around 70% of CH patients have satisfactory 
effect of verapamil, with an individual improvement of more than 75% 77. CH 
patients often need high verapamil doses compared to other indications, probably 
because the cardiovascular effects are directly related to blood levels of 
verapamil, whereas the effect on CH takes place across the blood brain barrier 
(BBB)78.  Verapamil easily crosses the BBB, although a P-glycoprotein restricts 
the brain uptake of verapamil by transporting it out of the brain78. An ECG is 
required before start of treatment, since there is a risk for development of 
atrioventricular block and symptomatic bradycardia in susceptible patients79. 
Verapamil is a calcium channel blocker, but the mechanism of action in CH is not 
clarified. A calcium channelopathy has been proposed to be a part of CH 
pathophysiology. Although verapamil is described as an L-type calcium blocker, 
the drug has possible effects on a range of other calcium channels, probably 
present in hypothalamus, the supposed centre of origin of CH pathophysiology78. 
Of the three isoforms of NO-synthases (NOS), nNOS, eNOS and iNOS, the 
activities of the first two are regulated by calcium-dependent influx into the cells80. 
In contrast, iNOS is calcium-independent, and the enzyme is not expressed 
unless the cells have been stimulated for example by certain cytokines like 
interferon-gamma and interleukin-181. A potential mechanism of action of 
verapamil would be inhibition of the calcium-dependent isoforms nNOS and 
eNOS which would support a pathophysiological role of nitric oxide in CH.  
 
When the CH attacks appear extremely often (5-8 times/day), the pain 
situation is intolerable. In this situation steroid medication is normally preferred, in 
order to achieve a rapid control of attacks. Usually 500 mg metylprednisone is 
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given intravenously over 3-5 days, followed by oral prednisone during 2-3 weeks. 
It is necessary to keep the steroid treatment short to avoid side-effects 68. 
Lithium carbonate is effective as a prophylactic drug, particularly for chronic 
cases, but has side-effects as hypothyroidism, tremor and renal dysfunction. 
Therefore, close control is needed to measure plasma lithium, renal and thyroid 
function68. 
Other prophylactic drugs are pizotifen, methyserigide and anti-epileptic 
drugs for example topiramate and valproate. 
 
 
 
Surgical treatment 
 
Surgical treatment should be considered with caution, because no long-
term observational data exist yet. For intractable CH when all medical therapy 
has failed, surgery might be an alternative. In some cases, blockade of the 
occipital nerve is effective and occipital nerve stimulation (ONS) could be a 
choice. The mechanisms of action for ONS are not clear, but PET studies have 
shown effects on central pain-modulating centres 82. ONS may also have direct 
impact on nociceptive neuronal activity in the trigeminal nucleus caudalis 83. 
Deep brain stimulation (DBS) of the posterior inferior hypothalamus has also 
been shown to be effective in nearly 60% of medically refractory chronic cluster 
headache patients84 
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 AIMS 
 
 
The overall objective of this thesis was to explore the participation of 
inflammation and nitric oxide in the pathophysiology of CH. 
 
Based on this, the specific objectives were: 
 
• To identify differentially expressed genes during different clinical phases 
of CH. 
• To investigate cytokine interleukin-2 (IL-2) as a possible marker of 
immune system involvement in the pathophysiology of CH. 
• To investigate if CH patients show signs of intracranial inflammation, with 
recruitment of white blood cells from the peripheral blood, when using 
white blood cell single photon emission computer tomography (WBC-
SPECT). 
• To investigate nitric oxide (NO) in CH by measuring its stable oxidation 
end products (NOx), nitrite and nitrate, in the cerebrospinal fluid (CSF). 
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 MATERIALS AND METHODS 
 
 
Patients and controls 
 
Only patients with episodic CH according to the IHS criteria1 in active period 
were included in the studies. Episodic CH is defined as attacks occurring in 
periods lasting 7 days to 1 year separated by pain-free periods lasting 1 month or 
longer. Chronic CH is defined as CH attacks occurring for more than 1 year 
without remission or with remissions lasting less than 1 month 1. All patients were 
followed with several phone interviews during the studies to check their CH 
“status”. This was important to enable separation of active period from remission, 
and to exclude patients who developed chronic CH. The phone calls were also a 
tool to prevent drop outs.  
 
Patients were defined in all studies as in active phase if they had repeated 
attacks during the last 4 days, and as in remission if no attacks had occurred 
within at least three weeks, except for Study III where absence of attacks within 
at least two weeks were regarded as in remission. The reason for the shorter 
time frame in Study III was logistical difficulties in the planning of repeated 
SPECT examinations and the need to avoid drop outs. To be included in all 
studies the patients had to be free from prophylactic treatment for at least three 
days before the study started. Patients started to scale down the medication a 
week before study start.  
 
All four studies had a longitudinal design, where the patients were 
examined in different phases of CH. Healthy controls were mainly members of 
the staff or other colleagues in study I, II and IV. In study III control subjects were 
recruited in connection with a routine SPECT examination, since the local 
Radiation Safety Committee would not admit healthy controls. The number of 
control subjects in study III was restricted due to the fact that almost all patients 
who came for routine SPECT had anti-inflammatory medication or antibiotics. 
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All studies were approved by the regional Ethics Committee and all patients 
provided their informed consent. 
 
The patient characteristics are listed in Figure 1. 
   
 
 
Patient  
No 
Gender Age at 
inclusion 
Prophylaxis
before 
inclusion 
Included 
in Study 
No 
 
1 Male 46 No I,II 
2 Male 40 No I,II 
3 Male 38 Verapamil I,II 
4 Male 39 No II,III,IV 
5 Male 63 No II 
6 Female 54 No II,IV 
7 Male 39 No II 
8 Female 54 No II 
9 Female 33 Verapamil III,IV 
10 Male 50 No III,IV 
11 Male 48 No III 
12 Male 31 Pizotifen III 
13 Female 32 No III 
14 Male 68 Verapamil III 
15 Male 40 Verapamil III 
16 Male 63 No III 
17 Male 26 No III 
18 Male 26 No III 
19 Male 37 No III 
20 Male 37 Topiramate III 
21 Male 67 Verapamil III 
22 Male 51 No IV 
23 Male 56 No IV 
24 Female 37 Verapamil IV 
25 Female 53 Verapamil IV 
26 Male 46 No IV 
27 Male 38 No IV 
28 Male 49 No IV 
29 Male 46 No IV 
30 Male 42 Verapamil IV 
31 Male 63 No IV 
 
Figure 1: Patient characteristics 
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Inclusion criteria in Study I-IV 
 
1. Episodic CH 
2. Active CH period during inclusion 
3. No prophylactic treatment for at least three days before study start 
4. Compliance regarding treatment 
5. Able to understand and follow instructions 
6. Willing to attend complementary examinations during remission 
7. Able to speak Swedish or English  
 
Patients had to be excluded for the following reasons: demanding workload 
in combination with active, excruciating CH; inadequate compliance regarding 
medication or logistical requirements; or symptoms in spontaneous regress 
before study start. Other patients who were included could not bear to be without 
prophylactic treatment. It is notable that the attack frequency rose markedly when 
patients during active bouts were withdrawn from prophylactic treatment. Retired 
patients, patients who were on sick leave and patient with irregular working hours 
were easier to include than others. For inclusion in the studies, an active phase 
was required, although the number of attacks could vary. An important factor  
was logistic demands and the life around patients. It is notable that the dropout 
frequency was rather high (Study II: 4 patients. Study III: 11patients. Study IV: 8 
patients). In study I there were no drop outs, but two patients were withdrawn due 
to poor RNA quality. The reasons for the dropouts varied, but a main problem 
was that patients did not shift into remission during the study time. Four patients 
in study IV, who developed postpunctional headache, did not want to go through 
a second LP in remission. 
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CH phases studied 
 
1. Active phase between attacks -  Study I-IV 
2. Active phase during attacks - Study I – II 
3. Remission - Study I-IV 
 
 
 
Methods  
 
1. Study I: Global gene expression in venous blood by use of PAXgene 
Blood RNA system, microarray and quantitative real-time polymerase 
chain reaction (RT-PCR) technologies. 
2. Study II: Gene expression of Interleukin-2 (IL-2) in venous blood by use 
of PAXgene Blood RNA system and RT-PCR technology.  
3. Study III: White blood cell uptake in defined regions of interest in the brain 
by the use of single photon emission computer tomography (WBC-
SPECT) and neuro-navigation with MRI. 
4. Study IV: Nitric oxide levels in cerebrospinal fluid by use of capillary 
electrophoresis. 
 
 
The PAXgene Blood RNA system 
Gene expression was studied in the first two publications. The physiological 
RNA instability results in rapid RNA degradation in blood samples85, 86. The 
PAXgene Blood RNA system is a method that preserves the RNA expression 
profile during and immediately after blood is drawn. The method is used for 
isolation of cellular RNA from whole blood. The stabilisation reagent contains a 
cationic detergent that is known to penetrate blood cells and interact with 
intracellular anionic species, including nucleic acids.  Once blood is drawn into 
the PAXgene tube, the detergent rapidly lyses red blood cells and enters white 
blood cells and forms stable complexes.  RNA is there for extracted from total 
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cells (i.e. both RBC and WBC)87. The cellular RNA profile may remain stable for 
up to 5 days at room temperature86. 
The influence of time on the quantity of complementary DNA (cDNA) using 
the PAXgene collection tubes was tested. Four blood samples from one single, 
healthy donor were collected into PAXgene tubes, and then left in room 
temperature for 2-12 hours before they were stored at 8°C until further processed. 
RNA was extracted according to the manufacturer’s recommendations day 1, day 
2, day 4 and day 5 after sampling. The extracted RNA from all samples was 
stored at - 70°C. The concentration of RNA was determined by ultraviolet 
absorbance at  260 nm. RNA was converted to cDNA using reverse transcriptase, 
since cDNA is more stable than RNA88. The quantity of mRNA expression was 
measured with real time quantitative polymerase chain reaction (RT-PCR) 
technique89. The test showed that the quantity of cDNA was maintained at an 
approximately constant level during 5 days following the blood sampling.  
 
Microarray technology 
This method has the ability to measure the level of expression for 
thousands of genes in one sample. The approach is screening rather than 
hypothesis driven. We have used Affymetrix-chip in study I (Affymetrix Human 
Genome U133 2.0 Plus GeneChip®). An Affymetrix-chip consist of 1.3 million90 
minimal squares, shared over an area of about 1 cm2. Every square consist of 
different sets of probes. (A probe is a labeled bit of DNA/ RNA used to find its 
complementary sequence). The Affymetrix-chip is constructed of single-stranded 
25 base pairs oligonucleotides synthesized for hybridization to complementary 
single-stranded cDNA, from the target tissue. While using extremely large 
amounts of identical probes in each square on the chip, the probability increases 
that complementary cDNA (the sample) hybridizates. The cDNA incorporates a 
detection reagent, a fluorescent dye. After hybridization the chip is scanned by a 
laser. The level of the hybridized probe will correspond to the amount of the 
cDNA. The oligonucleotides are synthesized in situ and located on the chip with 
extreme precision. The method is light-directed and is named photolithography91. 
A gene is represented on the chip by 11-20 unique probe pairs of 25 base pairs 
oligonucleotides. The probe pairs are designed as a Perfect Match (PM) and 
Mismatch (MM). The MM probes serve as control for hybridization91.   
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The advantages with the Microarray technology are obvious. With this 
method it is possible to receive information from a small amount of sample, 
regarding gene expression, about many thousands of genes. Due to the large 
amounts of results, this method can have a screening approach i.e. work as a 
generator of hypotheses. 
 
Disadvantages with the method are that high quality RNA is needed for 
reliable results and the high risk of false positive results when performing multiple 
testing. It might also be that not all observed intensities are associated with 
expressed genes, it could e.g. be noise due to non-specific binding or cross-
hybridization92. 
 
Before statistical analyses starts, the data have to go through several steps 
of quality control:  
 
Quality control 1: Total RNA quantity was determined by ultraviolet 
absorbance at 260 nm. The purity of the isolated RNA was determined by 
measuring the ratio of absorbance at 260 and 280 nm. 
  
Quality control 2: The signal intensity of all probes on each chip was scaled 
to a single value, 100, to allow comparisons between samples. 
 
Quality control 3: A quality control of reversed transcriptase. After 
hybridization the ratio between probe sets located in the 3’ and 5’ end, are 
counted for the control genes β-actin and GAPDH. 
 
Quality control 4: The PM/MM system. For each gene a set of paired 
oligonucleotide probes are designed. Each pair contains both a perfect match 
probe of the gene (a canonical sequence), and a mismatch probe (a mutation). 
The mismatch probe measures the degree of cross hybridization, i.e. false 
positive signals. 
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Quantitative Real-time polymerase chain reaction (Q-RT-PCR) 
Q-RT-PCR is a well-established and powerful method to quantify gene 
expression. With this method very small changes/differences in PCR products 
can be quantified. The method can be used to quantify DNA levels of for example 
viral infections and for gene expression analyses. To measure gene expression, 
mRNA is isolated and converted to cDNA before analysis. There are two different 
method of Q-RT-PCR; absolute and relative quantification89.  
 
When using absolute quantification the input transcript is determined with 
the use of a standard curve. In contrast, when using relative quantification the 
change in gene expression is compared to a reference gene (endogenous 
control). By using an endogenous control as a reference, quantification of mRNA 
can be normalized for differences in the amount of total RNA added to each 
reaction. Results are given as a dimensionless normalized ratio. 
 
To preserve the instant level of mRNA blood can be drawn with the 
PAXgene system described above, which includes RNA stabilizing buffer. mRNA 
is then converted to cDNA by the enzyme reverse transcriptase. The cDNA is 
subsequently amplified in the exponential PCR process, where the amplified 
product is recorded at each PCR cycle. Normally a high number (often 40) of 
repeated PCR are used in the Q-RT-PCR93.  
 
A PCR cycle contains a raise of the temperature to melt the double 
stranded cDNA or DNA, creating single stranded DNA that are used as new 
templates. The temperature of the reaction is then lowered, to enable the 
oligonucleotide primers to anneal to the new single stranded DNA. 
(primer=nucleic acid strand that serves as a starting point for DNA replication) 
The enzyme DNA polymerase will then initiate elongation of DNA by adding 
single complementary nucleotides, whereby a new double stranded DNA is 
created94. 
 
The final step is detection and quantification and there are several different 
methods for this. One example is when a DNA-based probe, complementary to 
the target nucleic acid molecule, is used. The probe is supplied with a fluorescent 
marker in one end and a quencher at the other end. When the DNA polymerase 
reaches the probe during the annealing stage, the fluorophore and quencher are 
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separated, resulting in a light of fluorescence, which is detected in every PCR 
cycle95. 
 
Q-RT-PCR is a stable method, but of course there are limitations, e.g. RNA 
is extremely labile and care has to be taken to avoid contamination with 
nucleases. 
 
 
 
 
 
White blood cell single photon emission computer tomography 
(WBC-SPECT) 
Tomographic techniques are giving cross-section images of the studied 
subject. When using SPECT the emitted gamma emission from the patient is 
counted in several well-known three-dimensional directions. For the purpose of 
studying white blood cell distribution in the body, these can be labelled with 
111Indium or 99mTecnetium. The latter is more preferable because of shorter 
investigation time and lower radiation burden to the patient. The SPECT images 
are usually acquired over 180° or 360 ° in small angular steps. Thereafter the 
concentration of activity can be calculated96. 
 
A balance must always be kept between resolution and sensitivity. Those 
qualities are competitive, and both are influenced by the choice of collimator. The 
collimator is often produced by lead and consists of several openings. Photons 
which are sent from the radionuclide have the same probability for all emission 
directions. A gamma camera without collimator cannot produce images, since the 
incoming directions of photons are not known. A collimator filters incoming 
photons and creates information about incoming directions 96. The construction of 
the collimator influences the resolution and sensitivity of the gamma camera, so 
that small openings in the collimator generate higher resolution and lower 
sensitivity. The distance between the gamma camera and the patient also 
influences the resolution of the images; the shorter the distance, the better the 
resolution96. 
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The following is a schedule for a WBC-SPECT: 
 
• The patient leaves a blood sample 
• White blood cells are separated and labeled with 99mTecnetium. 
• The blood sample with the 99mTecnetium-labeled WBC (99mTc-labeled    
 WBC) are re-infused to the patient 
• WBC migrates, besides the sites of physiological accumulation, to regions 
 of inflammation 
• A gamma camera register the radiation from the 99mTecnetium-labeled 
 WBC in the brain after 2 hours 
 
 
The 99mTecnetium-labeled re-injected WBC behaves like the native WBC 
and is distributed into a bound and a circulating part. Around 45 minutes after 
reinjection, balance has been reached and 40% of the injected activity is in the 
circulating blood and the rest of activity is equally distributed to the liver, spleen, 
lungs and bone marrow. Uptake in inflammatory regions is fast97.  
 
All CH patients and control patients in study III underwent an MRI of the 
brain to enable precisely anatomically defined regions of interest (ROI:s). All 
WBC-SPECT-studies were fused with the corresponding MRI using Hermes 
software (Hermes/NUD, Stockholm, Sweden). ROI:s were manually drawn on the 
MRI-images using anatomical borders without visual access to the WBC-SPECT-
images. SPECT images only are not sufficient for defining ROI:s due to the lack 
of anatomical landmarks and absence of high specific binding. 
 
 
 
 
 
 
 
 
 
24
Capillary electrophoresis     
 
In study IV we intended to investigate the role of NO in CH, by measuring 
its oxidation products (NOx); nitrite and nitrate, in the CSF. The reason for not 
measuring NO directly was that NO has a very short half-life, just 3-5 seconds81. 
To estimate NO production, we determined the levels of NOx by using capillary 
electrophoresis (CE). An advanced technique for the analysis of ions98, 99. The 
ions are separated on the bases of their charge ratio and allow individual 
detection of nitrite and titrate. CE has been shown to  quantify nitrite and nitrate 
in biological fluids close to the millimolar (mM) range100. The main components in 
CE are sample vial, source and destination vials, a capillary, electrodes, a high 
voltage power supply, a detector and computer, see Figure 2. The source vial, 
destination vial and capillary are filled with an electrolyte. The migration of the 
ions starts when the electric field is applied between the source and destination 
vials. A small volume of sample is injected at the positive end of the capillary and 
separated ions are detected near the negative end of the capillary. The output of 
the detector is sent to a computer98 (Figure 2). 
 
 
 
 
Figure 2: Diagram of CE system. (From Capillary Electrophoresis reference101)
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Statistics 
 
 
Study I 
 
The Affymetrix GeneChip® Operating Software (GCOS) version 1.0 was 
used for initial raw data processing. For comparison of different normalisation 
methods we used the Robust Multichip Average method102 implemented in the 
module Affy of the BioConductor microarray analysis software. For the relative 
gene expression levels, the GCOS Expression algorithm was used for transcript 
quantification and microarray data comparison.  
 
To enable identification of up- and downregulated genes between chip pairs, 
pairwise comparisons on signal values from different disease stages (period 
between attack, attack, remission) and controls were performed. Totally 6 
comparative analyses were performed. All samples were analysed in triplicates. 
A transcript had to be replicated as either increased or as decreased in all three 
samples to be regarded as a signal change.  
 
 
All probe IDs were checked against Affymetrix annotations, Netaffx analysis 
and annotation center at www.affymetrix.com/analysis/netaffx. 
 
 
Fischer´s exact test was used for comparisons of selected genes within a 
group of genes, upregulated S100 genes, compared to all genes represented on 
the chip. 
 
Statistical analysis on gene expression from the RT-PCR were performed 
between the disease stages (period between attack, attack, remission) by paired 
ANOVA, followed by Tukey-Kramer post test for multiple comparisons.  P<0.05 
was chosen to indicate statistical significance.   
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Study II 
 
Comparisons of relative IL-2 gene expression levels were performed by the 
use of Friedman´s ANOVA. Wilcoxon matched pairs tests were performed for 
dependent samples and Mann-Whitney U test for independent samples. P<0.05 
was chosen to indicate statistical significance.   
 
 
Study III 
 
A Mann-Whitney U test was used to investigate the difference in uptake 
between CH and control subjects. A Wilcoxon Matched Pairs test was used to 
compare the uptake in CH patients in active period and in remission and at pain 
side and non-pain side of cavernous sinuses. Both tests were implemented in 
Statistica 9.0 (StatSoft. Inc, Tulsa, Oklahoma, USA). Data were analyzed on the 
2 h post injection acquisitions. The significance level for statistical testing was 
taken p<0.05.  
 
 
Study IV 
 
Student´s t-test was used as we regarded the data to be normally 
distributed. A p-value of 0.05 was considered significant. Non-parametric test 
were also performed.  
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 RESULTS 
 
 
Study I 
 
Altogether small differences were seen intraindividually and large 
differences interindividually. Pairwise comparisons of signal values from different 
disease phases and controls, comparisons between different phases in the same 
individuals and between patients and matched controls, generated evidence of 
relatively few regulated genes. Results are presented as fold change in a log2 
ratio. The results are shown in Table 2, in study I.  
 
 All raw data are available at http://www.ebi.ac.uk/arrayexpress/browse.html? 
keywords=human+cluster+headache&expandefo=on . 
 
The most apparent finding was the upregulation of several calcium binding 
S100 genes; S100A8, S100A12, and S100P; during active period and attacks 
compared to remission (except for S100A12, which did not show upregulation 
during attacks). The S100A8 and S100A12 are considered markers of non-
infectious inflammatory disease, while the function of S100P has been connected 
to different forms of cancer103 . 
 
Moreover, Annexin 3 (also S100 protein like) was upregulated during 
attacks compared to remission. So were also ICAM3 and TNFRSF10C. The latter, 
TNFRSF10C is a member of the tumour necrosis family of genes, where all 
regulate cytokines. ICAM3 is an adhesion molecule, which is also regarded to be 
involved in the immune system. 
 
Fisher´s exact test was used for comparison of the S100 genes compared 
to all genes on the chip (~22 000 genes) which revealed an upregulation for 
period versus remission (p <0.0001), and for attack versus remission 
(p=0.00037). There were no significant differences for this transcript in relation to 
controls. 
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The upregulation of S100P could be confirmed with RT-PCR. The test 
showed significant differences between attacks and remission (p=0.048). Two 
patients had a higher expression level during period compared to attacks, but still 
both were higher compared to remission. Comparisons of all groups revealed 
significant differences between attacks and remission (p=0.025), see Figure 3. 
Patients in period showed no significant difference compared to remission and to 
controls (p=0.664 and p= 0.0146, respectively). Comparison of means between 
attack and controls was considered non-significant (p= 0.089.) The comparison 
between remission and controls was also considered not significant (p=0.15). 
The results were corresponding with the result from the microarray analysis, i.e. 
changes in S100P expression were seen within the same patients but not 
significantly in relation to controls, both in the microarray analysis and in the 
quantitative RT-PCR analysis.       
 
 
 
 
 
 
 
 
Figure 3: S100P relative gene expression levels. (Relative levels to GAPDH). Comparisons       
of all groups showed significant differences between attacks and remission (p=0.025).  
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Study II 
 
 
The relative gene expression of the cytokine IL-2 was studied in eight 
episodic CH patients and 16 healthy headache-free control subjects matched for 
age and gender. Venous blood samples were drawn from the CH patients on 
three occasions; during active period between headache attacks, during an 
attack and in remission. Venous blood samples were drawn once from each 
control subject. We analyzed IL-2 gene expression using RT-PCR.  
 
 
 
 
 
 
Figure 4: Relative IL-2 Expression in different phases of Cluster Headache.(Relative levels   
to GAPDH). * The p-values are compared to Between attacks.  
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Friedman’s ANOVA rejected the null hypothesis of no difference between 
the three phases (p=0.008). In pairwise comparisons, CH patients had 
significantly increased relative IL-2 gene expression values during active period 
between attacks (median 9.9, IQR 6.2-10.3) compared to in remission (median 
1.6, IQR 0.9-1.8, p=0.017) and control subjects (median 0.9, IQR 0.6-1.9, 
p=0.0001). The relative IL-2 gene expression values during the active period 
between attacks were also significantly higher than during attacks (median 2.8, 
IQR 0.7-3.2, p=0.012).  
 
A trend to higher relative IL-2 gene expression level was also noted during 
attacks in relation to controls and remission, although not statistically significant.  
 
The relative IL-2 expression value was deviating in one patient. The 
statistical analysis was repeated after exclusion of this patient, assuming that the 
value was an outlier; the difference between active period, remission and controls 
remained statistically significant. 
 
Relative IL-2 gene expression values among CH patients during different 
phases of the disorder and among healthy headache-free control subjects are 
presented in Fig 4. 
 
 
 
 
 
 
Study III 
 
14 CH patients and 5 control subjects were included in the study. The 
control subjects were all recruited in connection with a routine SPECT 
examination. Reasons for examination were suspected osteomyelitis in a knee or 
leg (2), infection around hip prostheses (1) and fever of unknown cause (2). None 
had signs of intracranial accumulation of white blood cells. 
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 A first visual evaluation of the MRI fused WBC-SPECT images revealed an 
intensive 99mTc-labeled WBC uptake in clivus in CH patients, independently of 
CH period, and also in controls. By contrast a low 99mTc-labeled WBC uptake 
was seen in the cavernous sinuses in CH patients, independently of CH period, 
and also in controls. 
 
The average labelling efficiency of WBC was 45% (range 17-72 %).  
 
 
 
 
 
 
 
Figure 5: The 99mTc-labeled WBC 2 h post injection uptake in cavernous sinus in CH patients, 
active phase and remission, compared to controls. Pain side indicates the side of the cavernous 
sinus ipsilateral to the CH attacks. Remission and controls include both sides of cavernous sinus. 
*p-values for comparison with pain side. **p-values for comparison with non-pain side. 
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The following normalised uptake was obtained for CH vs. controls, 
presented as median and interquartile range (cm-3; IQR): Cavernous sinus: 7.1 
(5.0-10.3) vs. 5.6 (4.6-6.8; p=0.34), sagittal sinus: 12.4 (11.3-14.2) vs. 10.5 (10.5-
11.3; p=0.09), clivus: 23.0 (14.5-30.5) vs. 24.2 (19.6-31.4; p=0.69.) 
 
No significant differences in normalized uptake were found in any of the 
regions listed above, when comparing CH patients in active period and remission.  
 
No conclusive increase of 99mTc WBC uptake at the CH pain side of the 
cavernous sinus compared to the non-pain side was seen.  Data are presented 
as: pain side median uptake (cm-3; IQR) vs. non pain side median uptake (cm-3; 
IQR): 7.7 (5.0-11.5) vs. 6.8 (4.8-9.0), (p=0.08). The results for the cavernous 
sinus, comparing CH pain side versus non pain side, CH in remission and 
controls, are shown as a box and whisker plot in Figure 5. 
 
In conclusion we found no significant difference in 99mTc-labeled WBC 
uptake at the CH pain side of the cavernous sinus compared to the non-pain side, 
although a trend to a higher uptake at the pain side was noted. Furthermore we 
found no significant difference in 99mTc-labeled WBC uptake between CH 
patients in active period and controls. CH patients in active period were not 
significantly different in uptake compared to CH patients in remission. 
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Study IV 
 
In study IV we included twenty-two CH patients during active period. 
Throughout the study, four patients developed chronic CH and four other patients 
discontinued due to postpunctional headache. The final study group consisted 
therefore of 14 CH patients. Eleven healthy volunteers served as control subjects.  
 
CH patients in the active period had significantly increased NOx levels 
(mean 9.3, 95% CI 8.5–10.1) compared with in remission (mean 7.6, 95% CI 
6.9–8.2; p<0.001) and control subjects (mean 6.2, 95% CI 4.9–7.5; p<0.001). 
(Figure 6). A significant difference was also present between CH patients’ NOx 
levels in remission and control subjects (p=0.034), where CH patients in 
remission had higher NOx levels.  
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Figure 6: Mean levels of nitric oxide products (NOx) in cerebrospinal fluid from episodic cluster 
headache patients during both phases of the disease, and also from controls 
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Thirteen of 14 CH patients showed higher NOx levels in the active period 
compared with remission.  
 
Two of the patients had a CH attack which started as the LP was performed. 
Their NOx levels were 9.6 µM and 10.3 µM. Two other CH patients had their last 
attacks 24 hours before the LP, and their NOx levels were 11.3 µM and 10.1 µM. 
All four patients showed deceased NOx levels in remission.  
 
Five patients had a nocturnal CH attack the night before the LP. The mean 
NOx levels were similar in this group compared with others (9.0 µM vs. 9.7 µM, 
NS).  
 
Clinical routine laboratory analyses of CSF showed normal levels with 
regard to protein content and inflammatory parameters in eight of 14 patients. A 
minor albumin increase in CSF was seen in five patients, for two of them both in 
the active phase and in remission. Two patients showed a modest albumin 
increase only in the active phase and one patient only in remission. A slight 
pleocytosis was seen in one patient in both phases of the disease. One patient 
showed solitary oligoclonal bands in CSF and plasma in remission. Patients with 
abnormalities in CSF parameters had slightly higher mean NOx levels than other 
patients (10.0 vs. 8.8 µM), although this difference was not statistically significant. 
None of the patients with changes in routine laboratory analyses presented any 
clinical symptoms of concomitant disease. 
 
Seven patients, i.e. about 50% (7 of 14), developed postpunctional 
headache. All seven of these patients developed postpunctional headache in the 
active period and three of them (three of 14) also developed postpunctional 
headache during remission. One of these patients also showed a minor albumin 
increase in CSF. If the four episodic CH patients who discontinued the study due 
to the development of postpunctional headache are also included, the 
percentage of CH patients who developed postpunctional headache during the 
active period increases to 61%. 
 
Finally, it was explored whether heterogeneity was present between the NO 
oxidation products, nitrite and nitrate, during the active period and in remission. 
 
 
35
Nitrite and nitrate levels were compared to the total NOx levels and found to be of 
similar distribution. 
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DISCUSSION 
 
 
The main objective of this thesis was to explore evidence of inflammatory 
involvement and the role of nitric oxide in the pathophysiology of CH. 
Inflammatory involvement was the focus in paper I-III and nitric oxide in paper IV. 
 
 
Inflammatory involvement in CH 
 
There are at least two major findings in this thesis which speak in favour of 
inflammatory involvement in CH. The first of these is the observation of 
upregulation of calcium binding S100 genes, such as S100A8 and S100A12 
during active period and attacks, compared to in remission. These two calcium 
binding genes are considered markers of non-infectious inflammatory diseases. 
The other is the increased relative IL-2 gene expression level during active period 
between headache attacks compared to during attacks, remission and controls. 
Both these findings provide support of a non-infectious inflammatory involvement 
in CH pathophysiology. Our observation of an upregulation of non-infectious 
inflammatory genes during active period and attacks compared to remission, are 
in agreement with earlier studies21, 22, 36-41, 43, e.g., Empl et al.21 who measured 
serum levels of soluble IL-2 receptors in 18 patients with CH and found 
significantly increased sIL-2R levels compared to headache-free control subjects. 
 
The exact mechanism of a non-infectious inflammation in CH is not known, 
but there are several potential modes of action that may contribute. Over recent 
years an increased understanding has developed on the role of a neurogenic 
inflammation closely related to the activation of the trigeminovascular system in 
CH and migraine. Release of CGRP and substance P from trigeminal fibers may 
initiate an inflammatory reaction with plasma protein release and 
vasodilation24, 34, 104.  Involvements of white blood cells have been suggested105.  
 
 Interestingly, IL-2 is vital for determining the magnitude and duration of 
primary and secondary immune responses, and moreover, one of its most 
important functions is to downregulate immune responses to protect against 
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autoimmunity106. Empl et al have shown that CH patients have significantly 
increased soluble IL-2 receptors in serum compared with controls21. Several 
earlier studies have shown a change in immunologically competent cells21, 38-40. 
Our finding of an increased IL-2 expression during active periods compared to 
remission and controls supports the concept of inflammatory involvement in CH. 
We also showed that IL-2 expression was reduced during attacks compared to 
active periods between attacks. It can be speculated that pain attacks are related 
to failure of protection against autoimmunity, but an alternate possibility is that 
the pain itself can cause a reduced IL-2 production107, 108 and this issue has to be 
resolved by further research.  In this context it is interesting that intrathecal 
delivery of a plasmid harbouring the IL-2 gene in rats produced a marked 
antinociceptive effect, which was maintained up to 6 days109. Moreover, IL-2 has 
been reported to activate the hypothalamus and stimulate the release of 
corticotropin-releasing factor (CRF)21, 110-113. 
 
Accumulation of white blood cells is a pivotal part of an immunological 
response and the documentation of white blood cell migration into the area of 
interest was in focus of the third paper. We decided to use a novel method in CH 
research with 99mTecnetium labeled white blood cells identified with SPECT in 
which the emitted gamma emission from the patient is counted in several 
predefined three-dimensional directions. MRI of the brain was used to enable 
precisely anatomically defined regions of interest (ROI:s). 
 
Our analyses of white blood cells within the central nervous system did not 
reveal findings of statistical significance. There was a trend to a higher uptake in 
the part of the cavernous sinus that was ipsilateral to the pain, but this 
observation is not conclusive. This is also true for another trend to higher uptake 
in the sagittal sinus. There is a possibility that these observations occurred by 
chance, but also that the method we used may have been too unspecific or that 
the study sample size too small. Although caution has to be applied in the 
interpretation of findings by multiple testing of white blood cell uptake at different 
locations, it may be of interest for further research.  
 
 
It may be interesting to note that our combination of SPECT with MRI 
enabled identification of uptake in clivus, which may otherwise have been 
 
 
38
interpreted as increased uptake in the cavernous sinus. The findings of Gawel et 
al41 who performed gallium-SPECT and found increased uptake of gallium in the 
region of cavernous sinus during active period could be supportive of our trend 
finding of increased WBC uptake in cavernous sinus, but the lack of 
neuroradiological navigation in their study also opened for the possibility of an 
influence from unspecific uptake in clivus.  
 
 
 
 
 
Nitric oxide in CH  
 
It is well known that administration an NO donor, such as nitroglycerin or 
histamine which causes release of NO from vascular sites, may induce  CH-like 
attacks during active CH phase but not during remission56. NO has a key role in 
regulating physiological functions, among these vasomotor regulation81. The 
isoform nNOS is expressed in most regions of the central nervous system, 
including the cerebellum, the cerebral cortex and various ganglion cells of the 
autonomic nervous system. Large numbers of nNOS-containing neurons have 
also been found in the hypothalamus111.  
 
Activation of the trigeminovascular system is considered an important step 
in the development of CH attacks24. CGRP is a marker of this activation, and 
increased levels have been found in blood from the external jugular vein during 
spontaneous CH attacks24, as well as attacks provoked by NO donors24, 45. 
D’Amico et al. have shown increased nitrite-levels in plasma among CH patients, 
both in active period and in remission 26. These findings, all together, indicate 
that there could be a link between NO, the trigeminovascular system and CH 
pathophysiology.  We intended to evaluate the role of NO in episodic CH, by 
analysing NOx in CSF, closer to the supposedly affected area in the 
hypothalamus. To our knowledge, a similar study has not been performed earlier. 
 
We were able to show that CH patients in active period had significantly 
increased NOx levels in CSF compared with those in remission and control 
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subjects. CH patients also had significantly enhanced NOx levels in remission 
compared to control subjects. 
 
Our results are in agreement with D’Amico et al.26, who found generally 
raised nitrite levels in plasma among CH patients, and adds support to the 
observation of a basal hyperactivity of the L-arginine-NO pathway.  
 
In another study by Costa et al., nitrite and L-citrulline (a stoichiometric 
metabolite, resulting from the conversion of L-arginine to NO, and considered as 
a reliable index of NOS activity) were measured in plasma in CH patients and 
controls after administration of nitroglycerin. The authors found no difference 
between the plasma concentrations of nitrite and L-citrulline between the two 
groups. They concluded that the result did not support the presence of a basal 
hyperactivity of the L-arginine-NO pathway in CH patients56. The discrepancy 
between our results and those of Costa et al. may be explained by differences in 
methodology. It is notable that the study of Costa et al. was performed on plasma 
rather than CSF, i.e. on a more remote substrate in relation to the brain. 
Furthermore Costa et al. studied induced attacks, while we studied spontaneous 
attacks. 
 
The level of NO production has been shown to correlate with disease 
activity in inflammatory disorders, such as multiple sclerosis, cystitis, cerebral 
systemic lupus erythematosus and inflammatory bowel disease65-67, 114, 115. The 
NOx levels in our study were higher during active period compared to remission, 
which correlates with our findings of increased expression of calcium binding 
S100 genes and IL-2 genes. This may suggest that increased NOx levels may be 
an expression of enhanced inflammatory activity in CH as well as in other 
inflammatory conditions. 
 
CH patients might be sensitized for CH attacks by a mechanism related to 
high NO-levels, and at a certain threshold, the trigeminovascular system is 
activated. High NO-levels may contribute to and maintain a central 
hyperalgesia59, 116-118. Possibly such a mechanism, in connection with activation 
of the trigeminovascular system, could be a source of the pain attacks.  
Interestingly, we found that headache occurring as a reaction to lumbar puncture 
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was overrepresented in CH and it can be speculated whether this is caused by 
sensitization secondary to enhanced NOx levels. 
 
In the trigeminal ganglion, CGRP and NOS co-localize in many neurons60. It 
has been suggested that NO causes release of CGRP61, 119, 120, although there 
are studies with conflicting results62, 63. Treatment of rat trigeminal ganglia 
cultures with NO donors caused a greater than four-fold increase in CGRP 
release compared with unstimulated cultures119.   
 
 
 
Inflammation and nitric oxide – an integrated 
discussion 
 
 Several mechanisms participate in the pathophysiology of CH. The clinical 
picture with frequent CH attacks, the diurnal pattern of attacks and hormonal 
alterations in CH patients have pointed to a potential defect in the 
suprachiasmatic nucleus within the hypothalamus15, 23 as the center of the origin 
of CH.  In hypothalamus large numbers of nNOS containing neurons have been 
found111. One hypothesis is that hypothalamus is responsible for producing 
boosts of NO, initiated by the suprachiasmatic nucleus. The NO-elevation might 
trigger the trigeminovascular system. 
  
 
One of the other cornerstones in CH pathophysiology is NO. We have 
shown generally raised NO levels in CSF in CH patients compared to healthy 
controls. The trigeminovascular system is activated in CH24, and one of the 
consequences may be neurogenic inflammation within its distribution34, 104. As 
mentioned above, CH patients might be sensitized for CH attacks by a 
mechanism related to high NO-levels, and at a certain threshold, the 
trigeminovascular system may be further activated. This may initiate a vicious 
circle, where both high NO-levels and neuropeptides, such as substance P and 
CGRP, contribute to a neurogenic inflammation. 
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The excruciating pain in CH might be related to high NO-levels and release 
of neuropeptides, giving rise to a neurogenic inflammation with sensitization of 
vessels and meninges, and inducing vasodilation. CH attacks are often 
successfully treated with sumatriptan or oxygen72 both of which are thought to 
induce their effect by vasoconstriction, indicating that vasodilation is involved in 
the generation of pain. 
 
Corticosteroids have positive therapeutic effect in CH25, 68. The isoform 
nNOS is expressed in most regions of the central nervous system and in 
hypothalamus111. The cytokine IL-2 can activate the hypothalamus and stimulate 
the release of corticotropin-releasing factor (CRF)21, 110-113, but the stimulatory 
effect of IL-2 on CRH release is inhibited by the corticosteroid 
dexamethasone111, 113, 121. In addition, treatment with dexamethasone in mouse 
inhibits the nNOS activity121. If these observations can be translated into the 
human brain, dexamethasone may inhibit the generation of a vicious circle by 
reducing the production of NO.  Subsequently, this would reduce the 
inflammatory activity and the activation of the trigeminal system. Many factors 
influence the immune system, complicating the interpretations of different 
interactions, such as pain, stress and other environmental factors107, 108. 
 
 
Limitations 
 
In all studies there are relatively small study populations.  The main reason 
for this is that CH is a rare episodic disorder and that patients had to be in active 
period for inclusion. Several patients could not be included since they would not 
accept to be without prophylactic treatment. There were also a number of 
logistical demands for the patients which made it difficult to motivate patients to 
join the studies. 
 
Unfortunately in paper I two out of five patients were withdrawn from the study, 
due to poor RNA quality. If it had been possible to get better RNA quality in the 
beginning, this could of course be avoided.  When we started this project RNA 
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extraction with PAXgene tubes was a new technique. Today the method has 
been evaluated further and there are reports how to receive better RNA quality, 
by using modified protocols122. 
 
In paper III measurements on three different SPECT cameras were performed 
due to the fact that the first camera was broken. We then had logistic problems to 
get time for the CH patients in the SPECT camera when they competed with 
clinical routine patients. 
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CONCLUSIONS 
 
Based on our studies comprising in total 31 patients and 35 controls, the 
following conclusions can be drawn.  
 
1. Our finding of an upregulation of S100A8 and S100A12 genes in CH 
patients during active period may indicate an inflammatory involvement in 
CH, since both S100A8 and S100A12 are considered markers of non-
infectious inflammatory disease. 
 
2. CH patients had significantly increased relative IL-2 gene expression 
between headache attacks during active CH period, compared to during 
attacks, remission and controls. This finding adds further support on 
involvement of inflammation in CH. Since a prominent function of IL-2 is 
defense against autoimmunity, our observation also may strengthen 
evidence that the inflammatory involvement is of noninfectious origin. 
  
3. The WBC-SPECT study did not provide statistically significant results. This 
might be due to the possibility that the method we used for this purpose is 
too unspecific, or the fact that WBC might not have a prominent role in CH. 
An important conclusion from the WBC-SPECT study is that MRI mapping 
is important to avoid misinterpretation. 
 
4. We have shown that CH patients in active period had significantly 
increased NOx levels in CSF compared with those in remission and with 
control subjects. CH patients also had significantly enhanced NOx levels 
in remission compared to control subjects. The level of NO production has 
been shown to correlate with disease activity in several inflammatory 
disorders. This suggests that increased NOx levels in CH patients might 
be an expression of enhanced inflammatory activity as well as in other 
inflammatory conditions. A connection between those two possible 
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5. We hypothesize that CH patients might be sensitized for CH attacks by a 
mechanism related to high NO-levels, and at a certain threshold, the 
trigeminovascular system is activated. The high NO-levels may also 
contribute to a central hyperalgesia. 
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